Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00893217 · ClinicalTrials.gov registry record · Phase 2
BEYOND Pilot Study
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT00893217: Completed Phase 2 study, sponsored by Bayer.
NCT00893217 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 71 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00893217, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to valuate safety and tolerability of Betaseron.
Interventions
- DRUG Betaseron (Interferon beta-1b, BAY86-5046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00893217 record still lists
NCT00893217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Betaseron (Interferon beta-1b, BAY86-5046) is the first listed.
NCT00893217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00893217 about?
NCT00893217 is a clinical study titled "BEYOND Pilot Study". The purpose of this study is to valuate safety and tolerability of Betaseron.
What is the current status of trial NCT00893217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2002-11. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00893217?
The interventions under investigation include: Betaseron (Interferon beta-1b, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00893217?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00893217's enrollment target sits among peer trials
71 936th of 2000 higher than 1,064 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia